Overall survival favored abemaciclib plus fulvestrant after disease progression on prior CDK4/6i & endocrine therapy. Numerically longer mOS 32 m. vs 25 m. Updated PFS, PFS2 & chemo-free survival all favored abemaciclib plus fulvestrant. $AZN $LLY #ESMO26 https://mededgemea.com/new-cancer-treatment-data-to-be-presented-at-esmo-congress-2026/
51 views · 0 likes · 0 reposts · 0 replies
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgAssociation of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2– high-risk early breast cancer: Results from monarchE
https://esmocongress.esmo.orgSource: MBC Advocate · x.com